Navigation Links
Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
Date:1/17/2008

LA JOLLA, Calif., Jan. 17 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced today that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of Diabetic Ulcers.

The Board of Immunosyn was advised as to the success of this important phase of the "Proof of Concept Trial" by Argyll Biotechnologies, LLC its strategic partner and largest shareholder. Argyll Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement.

The primary purpose of the "Proof of Concept Trial" is to further evaluate the safety and efficacy of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application.

Regarding the "Proof of Concept Trial," Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC stated that, "This first very important phase in the development of SF-1019, which was undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost certainly induces growth factors." "When systemically delivered, SF-1019 has shown the rapid resolution of long standing chronic lesions which is very impressive. And the topical application of SF-1019, while showing promise, in that a 5mm deep wound became closed, needs, as expected, unlike the subcutaneous method, more short-term development in order to improve the delivery methodology," he added.

Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP, has also advised that, "Because of the positive results, which both the independent clinical team and I have observed during the first phase of the "Proof of Concept
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Immunosyn Corporation Names Stephen Ferrone as CEO
2. Immunosyn Corporation to Begin Trading
3. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... The ISA (International Seabuckthorn Association) founded ... announced their 6th annual international conference to take place ... , Bruce McMullin , Founder and CEO of ... for introducing the benefits of sea buckthorn to the ... Sibu grows and harvests sea buckthorn berries in the ...
(Date:6/20/2013)... Indianapolis, IN (PRWEB) June 20, 2013 ... Many employers are concerned that this cost percentage will ... burden of caring for both aging parents and adult ... claims management can either provide workers a road block, ... , United Benefit Advisors (UBA), in ...
(Date:6/20/2013)... York, New York (PRWEB) June 20, 2013 ... protein folding and misfolding, Navneet Tyagi has ... Alzheimer’s disease. Throughout the myriad of scientific research that ... his commitment of identifying early onset of these severe ... through early diagnosis, more medical researchers will be able ...
(Date:6/20/2013)... Denton, TX (PRWEB) June 20, 2013 ... has maintained a wide range of outpatient and inpatient ... psychiatric issues, including those who are children. As a ... UBH explains that it is critical to diagnose mental ... action. However, according to a recent article ...
(Date:6/20/2013)... June 20, 2013 Rampant staph infections ... to fight this scourge is being successfully deployed by ... direct contact and by touching items that are contaminated ... As noted by the San Francisco Chronicle , ... become infected during hospital stays, and at least 90,000 ...
Breaking Medicine News(10 mins):Health News:Sibu, LLC CEO, Bruce McMullin to be Amongst Distinguished Attendees at ISA Conference 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 3Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 2Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 3Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 2Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 3Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 2Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 3
... gene respond well to targeted therapy , , SUNDAY, June ... the normal version of a particular gene are more ... adding the targeted therapy Erbitux to chemotherapy. , Some ... "wild-type" form of the gene, according to the new ...
... cells, hasten death, study says , , SUNDAY, June 1 ... in cancer patients may actually speed progression of the ... found a way to determine who those individuals are. ... whether a patient is susceptible to having their tumor ...
... study suggests , , SUNDAY, June 1 (HealthDay News) -- ... value in helping to prevent lung cancer. , Researchers ... on the U.S. market, may reduce levels of a ... presented its findings Sunday at the American Society of ...
... combination of two different biotherapies may be beneficial for ... Pittsburgh Cancer Institute (UPCI) study presented at the 44th ... (ASCO) in Chicago. , Researchers in the melanoma and ... treatments that stimulate the immune system to fight cancer ...
... common types, study says , , SUNDAY, June 1 (HealthDay News) ... or adolescents are much more likely than other people to ... disease (HD), a cancer of the lymph nodes, has a ... be at future risk of developing second cancers other than ...
... in determining how much fathers get involved in taking care ... of 97 couples found that fathers were more involved in ... encouragement from their wife or partner. , In fact, this ... mothers views about how involved dads should be, the overall ...
Cached Medicine News:Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2Health News:Mom's behavior key to dad's involvement in child care 2Health News:Mom's behavior key to dad's involvement in child care 3
(Date:6/20/2013)... WESTMINSTER, Colo. , June 20, 2013 ... Surefire Medical today announced a sales and marketing partnership ... catheters for the interventional radiology and oncology markets. ... range of products in the company,s rapidly growing ... . Sirtex reported a 30 per cent growth ...
(Date:6/20/2013)... , June 20, 2013 Today ... mark the launch of a new programme to control the ... Jacobina in the State of Bahia. In previous ... is possible to rapidly reduce the number of dengue mosquitoes ... the level of these mosquitoes were reduced by 96% within ...
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... suggested ibrutinib may be effective and generally well-tolerated in ... a separate study examining the safety and efficacy of ...
Breaking Medicine Technology:Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6
... Emdeon Inc. (NYSE: EM ), a leading provider ... acquisition of Chapin Revenue Cycle Management, LLC ("Chapin"). Based in ... revenue cycle services including accounts receivable management, medical denials, appeals and ... , ...
... June 21 TMS Health, a leading Healthcare Communications Company ... PA. , , ... TMS Health has enjoyed strong growth as a specialized healthcare ... and marketing reach of its clients. The company provides solutions for ...
Cached Medicine Technology:Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4TMS Health Announces New State-of-the Art Facility in Moosic, PA 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: